378 related articles for article (PubMed ID: 23436795)
21. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
22. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
23. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
24. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
25. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
26. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
[TBL] [Abstract][Full Text] [Related]
27. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
28. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.
Serra S; Zheng L; Hassan M; Phan AT; Woodhouse LJ; Yao JC; Ezzat S; Asa SL
Cancer Res; 2012 Nov; 72(22):5683-91. PubMed ID: 22986737
[TBL] [Abstract][Full Text] [Related]
29. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Orr-Asman MA; Chu Z; Jiang M; Worley M; LaSance K; Koch SE; Carreira VS; Dahche HM; Plas DR; Komurov K; Qi X; Mercer CA; Anthony LB; Rubinstein J; Thomas HE
Mol Cancer Ther; 2017 Nov; 16(11):2432-2441. PubMed ID: 28864682
[TBL] [Abstract][Full Text] [Related]
30. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
31. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
[TBL] [Abstract][Full Text] [Related]
32. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
33. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
35. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
36. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
[TBL] [Abstract][Full Text] [Related]
37. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
38. Everolimus causing severe hypertriglyceridemia and acute pancreatitis.
Subramaniam S; Zell JA; Kunz PL
J Natl Compr Canc Netw; 2013 Jan; 11(1):5-9. PubMed ID: 23307976
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
40. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]